SHARE
 
Natalie S. Callander, MD close

Natalie S. Callander, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Callander joined the section of Hematology/Bone Marrow Transplant at the University of Wisconsin in October 2004 as an Associate Professor in the Department of Medicine. Dr. Callander has completed residency at Bellevue Hospital in New York and a Hematology/Oncology fellowship at the University of California-San Diego.

Specialties

Clinics

UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map
UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Hematology
Internal Medicine
Medical Oncology
Fellowship University of California San Diego Medical Center, San Diego, CA
Residency Bellevue Hospital, New York, NY
Internship Bellevue Hospital, New York, NY
Medical School Tufts University School of Medicine, Boston, MA

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.
Research

Her clinical and research interests include: inpatient and outpatient care of hematology and bone marrow transplant patients and multiple myeloma.


PubMed Articles
Kim OM Jared JR Hennes ER Ninos CL Przybylski DJ Callander NS Flat-dose granulocyte colony-stimulating factor evaluation after autologous hematopoietic stem cell transplant in multiple myeloma patients: Does one dose fit all? J Oncol Pharm Pract . 2020 Oct 25;:1078155220968611
[PubMed ID: 33100179]
Dhakal B D'Souza A Callander N Chhabra S Fraser R Davila O Anderson K Assal A Badawy SM Berdeja J Cerny J Comenzo R Chakraborty R Peter Gale R Kamble R Kharfan-Dabaja MA Krem M Ganguly S Janakiram M Kansagra A Munker R Murthy H Patel S Kumar S Shah N Qazilbash M Hari P Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. Br J Haematol . 2020 Oct 23;
[PubMed ID: 33094839]
Jayakrishnan T Bakalov V Callander NS Sadashiv S Wagner R Ailawadhi S Impact of the Affordable Care Act on Timeliness to Treatment for Patients With Multiple Myeloma. Anticancer Res . 2020 Oct;40(10):5727-5734
[PubMed ID: 32988898]
Kumar SK Jacobus SJ Cohen AD Weiss M Callander N Singh AK Parker TL Menter A Yang X Parsons B Kumar P Kapoor P Rosenberg A Zonder JA Faber E Jr Lonial S Anderson KC Richardson PG Orlowski RZ Wagner LI Rajkumar SV Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol . 2020 Oct;21(10):1317-1330
[PubMed ID: 32866432]
Cornell R Hari P Tang S Biran N Callander N Chari A Chhabra S Fiala MA Gahvari Z Gandhi U Godby K Gupta R Jagannath S Jagosky M Kang Y Kansagra A Kauffman M Kodali S Kumar SK Lakshman A Liedtke M Lonial S Ma X Malek E Mansour J McGehee EF Neppalli A Paul B Richardson P Scott EC Shacham S Shah J Siegel DS Umyarova E Usmani SZ Varnado W Vij R Costa L Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. Am J Hematol . 2020 Sep 24;
[PubMed ID: 32974944]
Badar T Hari P Dávila O Fraser R Wirk B Dhakal B Freytes CO Rodriguez Valdes C Lee C Vesole DH Malek E Hildebrandt GC Landau H Murthy HS Lazarus HM Berdeja JG Meehan KR Solh M Diaz MA Kharfan-Dabaja MA Callander NS Farhadfar N Bashir Q Kamble RT Vij R Munker R Kyle RA Chhabra S Hashmi S Ganguly S Jagannath S Nishihori T Nieto Y Kumar S Shah N D'Souza A African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. Cancer . 2020 Sep 23;
[PubMed ID: 32966625]
Mushtaq MU Harrington AM Chaudhary SG Michaelis LC Carlson KB Abedin S Runass L Callander NS Fallon MJ Juckett M Hall AC Hematti P Mattison RJ Atallah EL Guru Murthy GS Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma . 2020 Sep 19;:1-9
[PubMed ID: 32951486]
Farooq AV Degli Esposti S Popat R Thulasi P Lonial S Nooka AK Jakubowiak A Sborov D Zaugg BE Badros AZ Jeng BH Callander NS Opalinska J Baron J Piontek T Byrne J Gupta I Colby K Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. Ophthalmol Ther . 2020 Sep 12;
[PubMed ID: 32920777]
D'Angelo CR Hall A Woo KM Kim K Longo W Hematti P Callander N Kenkre VP Mattison R Juckett M Decitabine induction with myeloablative conditioning and allogeneic hematopoietic stem cell transplantation in high-risk patients with myeloid malignancies is associated with a high rate of infectious complications. Leuk Res . 2020 Sep;96:106419
[PubMed ID: 32683127]
Costa LJ Derman BA Bal S Sidana S Chhabra S Silbermann R Ye JC Cook G Cornell RF Holstein SA Shi Q Omel J Callander NS Chng WJ Hungria V Maiolino A Stadtmauer E Giralt S Pasquini M Jakubowiak AJ Morgan GJ Krishnan A Jackson GH Mohty M Mateos MV Dimopoulos MA Facon T Spencer A Miguel JS Hari P Usmani SZ Manier S McCarthy P Kumar S Gay F Paiva B International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia . 2020 Aug 11;
[PubMed ID: 32778736]
Farooq AV Degli Esposti S Popat R Thulasi P Lonial S Nooka AK Jakubowiak A Sborov D Zaugg BE Badros AZ Jeng BH Callander NS Opalinska J Baron J Piontek T Byrne J Gupta I Colby K Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. Ophthalmol Ther . 2020 Jul 25;
[PubMed ID: 32712806]
Hennes ER Reed M Mably M Jared J Bergsbaken JJ Deming D Callander N O'Regan R Implementation of a chemotherapy stewardship process. Am J Health Syst Pharm . 2020 Jul 23;77(15):1243-1248
[PubMed ID: 32620961]
Wen Z Rajagopalan A Flietner E Yun G Chesi M Furumo Q Burns RT Papadas A Ranheim EA Pagenkopf AC Morrow ZT Finn R Zhou Y Li S You X Jensen JL Yu M Cicala A Menting J Mitsiades CS Callander NS Bergsagel PL Wang D Asimakopoulos F Zhang J Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice. Blood . 2020 Jul 8;
[PubMed ID: 32640012]
Lonial S Lee HC Badros A Trudel S Nooka AK Chari A Abdallah AO Callander N Lendvai N Sborov D Suvannasankha A Weisel K Karlin L Libby E Arnulf B Facon T Hulin C Kortüm KM Rodríguez-Otero P Usmani SZ Hari P Baz R Quach H Moreau P Voorhees PM Gupta I Hoos A Zhi E Baron J Piontek T Lewis E Jewell RC Dettman EJ Popat R Esposti SD Opalinska J Richardson P Cohen AD Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol . 2020 Feb;21(2):207-221
[PubMed ID: 31859245]
Lung DK Warrick JW Hematti P Callander NS Mark CJ Miyamoto S Alarid ET Bone Marrow Stromal Cells Transcriptionally Repress ESR1 but Cannot Overcome Constitutive ESR1 Mutant Activity. Endocrinology . 2019 Oct 1;160(10):2427-2440
[PubMed ID: 31504407]
Dhakal B Pagenkopf A Mushtaq MU Cunningham AM Flietner E Morrow Z Papadas A Hope C Leith C Hematti P Hari P Callander NS Asimakopoulos F Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma. Leuk Lymphoma . 2019 Oct;60(10):2558-2562
[PubMed ID: 30845856]
Gandhi UH Cornell RF Lakshman A Gahvari ZJ McGehee E Jagosky MH Gupta R Varnado W Fiala MA Chhabra S Malek E Mansour J Paul B Barnstead A Kodali S Neppalli A Liedtke M Narayana S Godby KN Kang Y Kansagra A Umyarova E Scott EC Hari P Vij R Usmani SZ Callander NS Kumar SK Costa LJ Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia . 2019 Sep;33(9):2266-2275
[PubMed ID: 30858549]
Jackson ER Jared JR Piccolo JK Woo KM Mably MS Reed MP Callander NS Granulocyte colony-stimulating factor utilization postautologous hematopoietic stem cell transplant in multiple myeloma patients: Does one size fit all? J Oncol Pharm Pract . 2019 Jul;25(5):1135-1141
[PubMed ID: 29890920]
Inamoto Y Petri�ek I Burns L Chhabra S DeFilipp Z Hematti P Rovó A Schears R Shah A Agrawal V Ahmed A Ahmed I Ali A Aljurf M Alkhateeb H Beitinjaneh A Bhatt N Buchbinder D Byrne M Callander N Fahnehjelm K Farhadfar N Gale RP Ganguly S Hashmi S Hildebrandt GC Horn E Jakubowski A Kamble RT Law J Lee C Nathan S Penack O Pingali R Prasad P Pulanic D Rotz S Shreenivas A Steinberg A Tabbara K Tichelli A Wirk B Yared J Basak GW Battiwalla M Duarte R Savani BN Flowers MED Shaw BE Valdés-Sanz N Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant . 2019 May;25(5):e145-e154
[PubMed ID: 30521975]
Inamoto Y Petri�ek I Burns L Chhabra S DeFilipp Z Hematti P Rovó A Schears R Shah A Agrawal V Al-Khinji A Ahmed I Ali A Aljurf M Alkhateeb H Beitinjaneh A Bhatt N Buchbinder D Byrne M Callander N Fahnehjelm K Farhadfar N Gale RP Ganguly S Hildebrandt GC Horn E Jakubowski A Kamble RT Law J Lee C Nathan S Penack O Pingali R Prasad P Pulanic D Rotz S Shreenivas A Steinberg A Tabbara K Tichelli A Wirk B Yared J Basak GW Battiwalla M Duarte R Savani BN Flowers MED Shaw BE Valdés-Sanz N Correction: Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transplant . 2019 May;54(5):782-783
[PubMed ID: 30809032]